查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830971

不孕不孕检测市场

Infertility Testing Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

不孕症检测市场预计将从 2024 年的 5.0029 亿美元扩大到 2031 年的 8.9096 亿美元，2025-2031 年期间的复合年增长率预计为 8.6%。

市场洞察与分析师观点：男性和女性不孕症发病率的上升以及不孕症检测技术的进步推动了市场的成长。然而，市场扩张受到认知度不足和不孕症检测试剂盒限制的阻碍。

生殖健康领域的不孕症是指不会损害身体功能或构成生命危险，但却会影响个人发展并导致个人（男性和女性）沮丧的疾病。大约有 5,000 万到 8,000 万对夫妇在其育龄期间至少会面临一次不孕不育的挑战。发展中国家和已开发国家之间的不孕症盛行率有所不同。世界卫生组织 (WHO) 报告称，六分之一的夫妇患有不孕症问题。人们对检测的认识不断提高，加上生活方式的改变和不健康的饮食趋势会导致不孕症和妇科疾病，这些因素正在推动不孕症检测市场的扩张。此外，排卵监测技术的进步也进一步推动了市场的成长。烟草和吸烟消费的增加预计会提高不孕不育率，从而增加对不孕症检测的需求。此外，生育意识的增强、受多囊性卵巢症候群影响的女性人数的增加、两性对自我检测和远端监控的需求不断增长以及创新产品的推出，都可能为预测期内的不孕症检测市场创造机会。

成长动力：男性和女性不孕症发病率上升推动市场成长男性不孕症是全球普遍存在的问题，不同地区的盛行率各不相同。世界卫生组织指出，约 20% 的不孕夫妇有男性相关的不孕问题，而 30% 的夫妇则面临双方共同的不孕症挑战。导致男性不孕的关键因素包括脑下垂体激素水平低、精液缺陷和品质差、影响精液进入阴道的性功能障碍以及存在精子抗体。美国卫生与公众服务部称，精索静脉曲张（睪丸静脉扩张）是精子数量低的最常见原因，影响约 40% 的不孕男性。男性不孕症病例的增加推动了对不孕检测的需求。

在全球范围内，由于晚婚和与年龄相关的不孕症等多种因素，生育率正在下降。世界卫生组织估计，2020年全球15至49岁成年人中约有1.285亿新发衣原体感染病例，女性盛行率为4.0%，男性盛行率为2.5%。美国疾病管制与预防中心（CDC）报告称，美国约有10%（610万）15至44岁女性在怀孕或维持妊娠方面遇到困难。因此，生育率下降推动了对不孕症检测的需求，以确定男性和女性不孕不育的原因，从而推动市场成长。

策略洞察报告细分和范围：「不孕症检测市场分析」是透过检查以下细分进行的：类型、测试套件、样本和最终用户。

細項分析：不孕症检测市场分为男性不孕症检测和女性不孕症检测。 2022年，女性不孕症检测占据了更大的市场份额，而男性不孕症检测预计在预测期内将实现9.2%的复合年增长率。压力增加、肥胖、吸烟和饮酒等因素会导致男性不孕不育。此外，人们对不孕症的认识不断提高、研发支出增加、主要参与者推出新产品的倡议以及生活方式的改变，都在推动男性不孕症检测领域的成长。

就检测试剂盒而言，不孕症检测市场分为人类卵泡刺激素 (FSH) 检测试剂盒、人类绒毛膜促性腺激素 (HCG) 检测试剂盒、黄体生成素 (LH) 检测试剂盒等。人类卵泡刺激素 (FSH) 检测试剂盒细分市场在 2022 年占据最大市场份额，预计在预测期内将录得 9.2% 的最高复合年增长率。 FSH 检测试剂盒可测量血液中的 FSH 荷尔蒙浓度，这对于评估生育问题、更年期和性发育问题至关重要。 FSH 调节女性的月经週期和男性的精子生成，使其成为生殖健康的重要诊断工具。此外，生物相似药 FSH 产品的进步、监管部门的批准以及 FSH 试剂盒生产的技术创新预计将推动全球市场成长。

依样本类型，不孕症检测市场可细分为血液、尿液和其他样本。血液样本在2022年占据最大市场份额，预计在预测期内将达到9.1%的最高复合年增长率。不孕症检测通常涉及血液检测以测量关键激素，男性和女性根据其具体情况需要进行不同的检测。 2021年1月，健康新创公司Yesmom推出了亚洲首款家用女性生育力血液检测试剂盒，让女性能方便地专注于生殖健康。

依终端用户划分，不孕症检测市场分为医院和诊所、生育中心和家庭护理。家庭护理领域在2022年占据了最大的市场份额，预计在预测期内将实现9.0%的最高复合年增长率。这一增长归因于患者对自我监测健康状况的偏好、透过电商平台轻鬆获取生育检测试剂盒、用户友好型设备的普及以及对检测结果保密性的日益增长的需求。

辅助生殖技术 (ART) 和体外受精 (IVF) 的采用将推动不孕症检测市场的发展。随着人们对不孕症问题的认识不断提高，未来几年 IVF 和 ART 治疗的需求可能会持续增长。先进的卵胞浆内单精子注射技术的引入，以及人们对药物和手术 IVF 程序的认知度不断提升，预计将在预测期内推动不孕症检测市场的发展。根据加州大学旧金山分校健康中心的数据，约 10% 的不孕症病例归因于不明原因，而 30% 的不孕症病例则与伴侣双方的问题有关。

男性常见的治疗手段包括卵胞浆内单一精子注射 (ICSI)、附睪穿刺、输精管穿刺、睪丸精子萃取、睪丸衰竭定位。约 75% 的男性不孕症患者存在可识别或可治疗的疾病。此外，几乎所有男性不孕症患者都可以透过辅助生殖技术 (ART) 治疗。因此，ART 和 IVF 的普及率不断提升，很可能在未来几年引领不孕检测市场的新趋势。

区域分析：不孕症检测市场报告涵盖北美、欧洲、亚太、南美和中美以及中东和非洲。

2022年，北美占据了不孕症检测市场的最大份额。该地区的成长动力源自于以下因素：不孕不育盛行率高、男女不孕症检测意识增强、女性初次怀孕年龄上升，以及透过电商平台轻鬆取得不孕症检测试剂盒。此外，吸烟和烟草使用率的上升预计将导致不孕不育病例增加，从而进一步推动市场成长。检测意识的增强以及受多囊性卵巢症候群 (PCOS) 影响的女性人口不断增加，也加速了市场扩张。

预计欧洲将占据全球不孕症检测市场的第三大份额。欧洲市场的成长得益于人们对不孕不育问题认识的提高、糖尿病患者的不断增长、众多市场参与者的存在以及政府在生育方面的倡议。根据欧洲人类生殖与胚胎学会的数据，预计2021年欧洲将有超过2,500万人受到不孕症的影响。在欧洲，每个小学班级都会有一名儿童透过辅助生殖技术（ART）出生；在北欧国家，2%至7%的新生儿是透过ART技术出生的。西班牙凭藉其完善的法律架构、大量的不孕症专业人员、优良的设施和先进的医疗技术，成为不孕症治疗的首选目的地。欧洲生育协会 (FE) 是 20 多个国家参与不孕症问题的欧洲协会的伞式组织，旨在改善不孕症患者的权利，在欧洲患者之间建立强大的跨境网络，提高社会对不孕症的认识，并加强生殖健康保护教育。

预计亚太地区不孕症检测市场在预测期内将达到9.1%的最快成长率。这一区域成长归因于受生活方式相关疾病影响的女性人数不断增加、不孕症检测产品开发投资的不断增加，以及国内外企业对亚太地区不孕症检测市场的日益关注。

不孕症检测市场报告范围：产业发展与未来机会：不孕症检测市场预测可以帮助利害关係人规划其成长策略。以下是市场领导企业报告的一些策略发展：

2023 年 7 月，全球领先的自我诊断测试公司 2San 与 Proov 合作，在美国中西部八个州的指定 Hy-Vee 门市推出了独家、用户友好的家用生育测试。 2022 年 1 月，着名的生育和家庭建设护理提供者 Kindbody 推出了其消费产品部门 Kind at Home，旨在为个人的整个生殖旅程提供支持，首先是针对男性和女性的用户友好的家用生育激素测试。 2021 年 12 月，Carrot Fertility 推出了一款新套件，旨在帮助个人在家中监测生育激素和相关生物标誌物，提供全面的生育健康状况视图，并支持在家中舒适地进行主动干预。竞争格局和主要公司：不孕不育测试市场报告中介绍的主要公司包括默克集团、宝洁、bioMerieux SA、Alere Inc.、Babystart Ltd.、bioZhena Corporation、Quidel Corporation、CENTOGENE NV、SCSA Diagnostics， Inc. 和 Boditech Med Inc. 这些公司专注于开发新技术、改进现有产品并扩大其全球的需求，

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：不孕症检测市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：不孕症检测市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：不孕症检测市场－全球市场分析

  • 不孕症检测 - 全球市场概览
  • 不孕症检测－全球市场及2031年预测

第七章：不孕症检测市场-收入分析-依类型，2021-2031

  • 概述
  • 女性不孕不孕检测
  • 男性不孕症检测

第 8 章：不孕症检测市场 - 收入分析 - 依检测试剂盒分类，2021-2031 年

  • 概述
  • 人类促卵泡激素（FSH）尿液检测试剂盒
  • 人类绒毛膜促性腺激素（HCG）血液检测试剂盒
  • 黄体生成素（LH）检测试剂盒
  • 其他的

第九章：不孕症检测市场-收入分析-依样本，2021-2031

  • 概述
  • 血
  • 尿
  • 其他的

第 10 章：不孕症检测市场 - 收入分析 - 按最终用户，2021-2031 年

  • 概述
  • 医院和诊所
  • 生育中心
  • 居家护理

第 11 章：不孕症检测市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 13 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 14 章：不孕症检测市场 - 主要公司简介

  • Merck KGaA
  • Procter & Gamble
  • bioMerieux SA
  • Alere Inc.
  • Babystart Ltd.
  • bioZhena Corporation
  • Quidel Corporation
  • SCSA Diagnostics, Inc.
  • CENTOGENE N.V.
  • Boditech Med Inc.

第 15 章：附录

简介目录
Product Code: TIPHE100001421

The infertility testing market is anticipated to expand from US$ 500.29 million in 2024 to US$ 890.96 million by 2031, with an estimated CAGR of 8.6% during the period of 2025-2031.

Market Insights and Analyst View:The growth of the market is driven by the rising incidence of infertility among both men and women, along with advancements in infertility testing technologies. However, the market's expansion is hindered by a lack of awareness and the limitations of infertility testing kits.

Infertility, in the context of reproductive health, refers to a condition that does not impair physical functioning or pose a life-threatening risk, yet it can impact personal development and lead to frustration for individuals (both men and women). Approximately 50 to 80 million couples face infertility challenges at least once during their reproductive years. The prevalence of infertility varies between developing and developed nations. The World Health Organization (WHO) reports that one in six couples experiences infertility issues. Growing awareness of testing, coupled with lifestyle changes and unhealthy dietary trends contributing to infertility and gynecological disorders, is driving the expansion of the infertility testing market. Additionally, advancements in ovulation monitoring technologies are further propelling market growth. Increased tobacco and smoking consumption is expected to raise infertility rates, thereby increasing the demand for infertility testing. Furthermore, heightened awareness of fertility, the rising number of women affected by PCOS, the growing demand for self-testing and remote monitoring among both genders, and the introduction of innovative products are likely to create opportunities for the infertility testing market in the forecast period.

Growth Drivers:Rising Incidence of Infertility in Men and Women Fuels Market Growth

Male infertility is a widespread issue globally, with varying prevalence across regions. The WHO indicates that approximately 20% of infertile couples have male-related infertility issues, while 30% of couples face infertility challenges due to both partners. Key factors contributing to male infertility include low hormone levels produced by the pituitary gland, deficiencies in semen and its quality, sexual dysfunctions affecting semen entry into the vaginal canal, and the presence of sperm antibodies. Varicocele, an enlarged vein in the testicle, is the most common cause of low sperm count, affecting about 40% of men with infertility issues, according to the US Department of Health and Human Services. The increase in male infertility cases is driving the demand for infertility testing.

Globally, fertility rates are declining due to various factors, including delayed marriages and age-related infertility. The WHO estimated that in 2020, there were around 128.5 million new chlamydia infections among adults aged 15-49 worldwide, with a prevalence of 4.0% in women and 2.5% in men. The Centers for Disease Control and Prevention (CDC) reports that about 10% of women (6.1 million) aged 15 to 44 in the US experience difficulties in conceiving or maintaining pregnancy. Consequently, the declining fertility rates are driving the demand for infertility testing to identify the causes of infertility in both men and women, thus propelling market growth.

Strategic Insights

Report Segmentation and Scope:The "infertility testing market analysis" has been conducted by examining the following segments: type, test kits, sample, and end user.

Segmental Analysis:The infertility testing market is divided into male infertility testing and female infertility testing segments. The female infertility testing segment held a larger market share in 2022, while the male infertility testing segment is expected to achieve a higher CAGR of 9.2% during the forecast period. Factors such as increased stress, obesity, smoking, and alcohol consumption contribute to male infertility. Additionally, rising awareness about infertility, increased R&D spending, initiatives by key players to launch new products, and changing lifestyles are driving growth in the male infertility testing segment.

In terms of test kits, the infertility testing market is categorized into human follicular stimulating hormone (FSH) test kits, human chorionic gonadotropin (HCG) hormone test kits, luteinizing hormone (LH) test kits, and others. The human follicular stimulating hormone (FSH) test kits segment held the largest market share in 2022 and is projected to record the highest CAGR of 9.2% during the forecast period. FSH test kits measure the concentration of FSH hormone in the blood, which is crucial for assessing fertility issues, menopause, and sexual development problems. FSH regulates the menstrual cycle in women and sperm production in men, making it an essential diagnostic tool for reproductive health. Furthermore, advancements in biosimilar FSH products, regulatory approvals, and technological innovations in FSH kit production are expected to drive global market growth.

By sample type, the infertility testing market is segmented into blood, urine, and others. The blood segment held the largest market share in 2022 and is anticipated to achieve the highest CAGR of 9.1% during the forecast period. Infertility tests typically involve blood tests to measure key hormones, with different tests required for men and women based on their specific situations. In January 2021, health startup Yesmom launched Asia's first at-home female fertility blood test kits, enabling women to prioritize their reproductive health conveniently.

By end user, the infertility testing market is divided into hospitals & clinics, fertility centers, and homecare. The homecare segment held the largest market share in 2022 and is expected to register the highest CAGR of 9.0% during the forecast period. This growth is attributed to patients' preference for self-monitoring health conditions, easy access to fertility testing kits via e-commerce platforms, the availability of user-friendly devices, and a growing desire for confidentiality regarding test results.

Adoption of Assisted Reproductive Technologies (ART) and In Vitro Fertilization (IVF) to Boost Infertility Testing Market

Increasing awareness of infertility is likely to drive demand for IVF and ART treatments in the coming years. The introduction of advanced intra-cytoplasmic sperm injection techniques and rising awareness of medicinal and surgical IVF procedures are expected to propel the infertility testing market during the forecast period. According to UCSF Health, approximately 10% of infertility cases are attributed to unknown causes, while 30% are due to issues in male and female partners.

Common procedures for men include intracytoplasmic sperm injection (ICSI), epididymal aspirations, vasal aspiration, testicular sperm extraction, and mapping of failing testes. About 75% of men with male factor infertility have identifiable or treatable conditions. Moreover, nearly all men with male factor infertility can be treated with ARTs. Therefore, the increasing adoption of ART and IVF is likely to introduce new trends in the infertility testing market in the coming years.

Regional Analysis:The infertility testing market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America accounted for the largest share of the infertility testing market. The growth in this region is driven by the high prevalence of infertility, increased awareness of infertility testing among both genders, the rising age of first pregnancies among women, and the easy availability of infertility test kits through e-commerce platforms. Additionally, the rising rates of smoking and tobacco use are expected to contribute to increased infertility cases, further propelling market growth. Growing awareness of testing and the increasing female population affected by PCOS are also accelerating market expansion.

Europe is projected to hold the third-largest share of the global infertility testing market. The growth in the European market is fueled by heightened awareness of infertility issues, a growing diabetic population, and the presence of numerous market players along with government initiatives related to fertility. According to the European Society of Human Reproduction and Embryology, infertility was estimated to affect over 25 million people in Europe in 2021. In Europe, one child per primary school class is born through assisted reproductive technologies (ART), and in Nordic countries, between 2% and 7% of births result from ART. Spain is a preferred destination for infertility treatment due to its progressive legal framework, high number of infertility professionals, excellent facilities, and advanced medical technologies. Fertility Europe (FE) is the umbrella organization for European associations involved in infertility issues across over 20 countries, aiming to improve the rights of those affected by infertility, foster a strong cross-border network among European patients, promote social awareness about infertility, and enhance education in reproductive health protection.

The Asia Pacific infertility testing market is expected to experience the fastest growth rate of 9.1% during the forecast period. This regional growth is attributed to the increasing number of women affected by lifestyle-related disorders, rising investments in the development of infertility testing products, and a heightened focus from both international and domestic players on the Asia Pacific infertility testing market.

Infertility Testing Market Report ScopeIndustry Developments and Future Opportunities:The infertility testing market forecast can assist stakeholders in planning their growth strategies. Below are some strategic developments reported by leading players in the market:

In July 2023, 2San, a global leader in self-diagnostic testing, partnered with Proov to launch exclusive, user-friendly at-home fertility tests at select Hy-Vee stores across eight Midwestern states.In January 2022, Kindbody, a prominent fertility and family-building care provider, launched Kind at Home, its consumer products division aimed at supporting individuals throughout their reproductive journey, starting with user-friendly home fertility hormone tests for both women and men.

In December 2021, Carrot Fertility introduced a new kit designed to help individuals monitor fertility hormones and related biomarkers at home, providing a comprehensive view of fertility health and enabling proactive interventions from the comfort of home.

Competitive Landscape and Key Companies:Key companies profiled in the infertility testing market report include Merck KGaA, Procter & Gamble, bioMerieux SA, Alere Inc., Babystart Ltd., bioZhena Corporation, Quidel Corporation, CENTOGENE N.V., SCSA Diagnostics, Inc., and Boditech Med Inc. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing consumer demand worldwide.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Infertility Testing Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Infertility Testing Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Infertility Testing Market - Global Market Analysis

  • 6.1 Infertility Testing - Global Market Overview
  • 6.2 Infertility Testing - Global Market and Forecast to 2031

7. Infertility Testing Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Female Infertility Testing
  • 7.3 Male Infertility Testing

8. Infertility Testing Market - Revenue Analysis (USD Million) - By Test Kits, 2021-2031

  • 8.1 Overview
  • 8.2 Human Follicular Stimulating Hormone (FSH) Urine Test Kits
  • 8.3 Human Chorionic Gonadotropin (HCG) Hormone Blood Test Kits
  • 8.4 Luteinizing Hormone (LH) Test Kits
  • 8.5 Others

9. Infertility Testing Market - Revenue Analysis (USD Million) - By Sample, 2021-2031

  • 9.1 Overview
  • 9.2 Blood
  • 9.3 Urine
  • 9.4 Others

10. Infertility Testing Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals & Clinics
  • 10.3 Fertility Centers
  • 10.4 Homecare

11. Infertility Testing Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Infertility Testing Market Overview
    • 11.1.2 North America Infertility Testing Market Revenue and Forecasts to 2031
    • 11.1.3 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Type
    • 11.1.4 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Test Kits
    • 11.1.5 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Sample
    • 11.1.6 North America Infertility Testing Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Infertility Testing Market
        • 11.1.7.1.1 United States Infertility Testing Market, by Type
        • 11.1.7.1.2 United States Infertility Testing Market, by Test Kits
        • 11.1.7.1.3 United States Infertility Testing Market, by Sample
        • 11.1.7.1.4 United States Infertility Testing Market, by End User
      • 11.1.7.2 Canada Infertility Testing Market
        • 11.1.7.2.1 Canada Infertility Testing Market, by Type
        • 11.1.7.2.2 Canada Infertility Testing Market, by Test Kits
        • 11.1.7.2.3 Canada Infertility Testing Market, by Sample
        • 11.1.7.2.4 Canada Infertility Testing Market, by End User
      • 11.1.7.3 Mexico Infertility Testing Market
        • 11.1.7.3.1 Mexico Infertility Testing Market, by Type
        • 11.1.7.3.2 Mexico Infertility Testing Market, by Test Kits
        • 11.1.7.3.3 Mexico Infertility Testing Market, by Sample
        • 11.1.7.3.4 Mexico Infertility Testing Market, by End User
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East & Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East & Africa
  • 11.5 South & Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South & Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Infertility Testing Market - Key Company Profiles

  • 14.1 Merck KGaA
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Procter & Gamble
  • 14.3 bioMerieux SA
  • 14.4 Alere Inc.
  • 14.5 Babystart Ltd.
  • 14.6 bioZhena Corporation
  • 14.7 Quidel Corporation
  • 14.8 SCSA Diagnostics, Inc.
  • 14.9 CENTOGENE N.V.
  • 14.10 Boditech Med Inc.

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud